Replies to post #432 on Geron Corp (GERN)

[esammee]

There's certainly value in that proposition. The big However is that Geron has made it pretty clear that they, through basic research, are developing the IP and don't necessarily plan on taking it through to treatments, but rather would prefer licensing and royalties. Except for 163L of course, but at one point they even had a partner for that. It seems to me that Geron is working towards being the QCOM of the biotech sphere.

p.s. thanks for those other links. They don't do any good if he won't read them and he hasn't. His DD is so far behind that he doesn't even know about Geron Bio-Med in the present tense.